Obinutuzumab(Roche / Genentech)은 B-cell Lymphoma 표적 항체로, Breast Adenocarcinoma; Metastatic Breast Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: targets type I interferon signaling. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 100% (ClinicalTrials.gov NCT02611323). 차별점: novel calcineurin inhibitor with predictable pharmacokinetics, increases complete renal response rates and rapidly reduces pr.
B-cell Lymphoma
Breast Adenocarcinoma; Metastatic Breast Carcinoma
Recruiting
bispecific antibody approved for treatment of relapsed/refractory diff
AAV)
humanized type II anti-CD20 monoclonal antibody, is designed for more potent and sustained B-cell depletion w
novel calcineurin inhibitor with predictable pharmacokinetics, increases complete renal response rates and rapidly reduces pr
targets type I interferon signaling
Cytokine release syndrome occurred in all glofitamab-treated patients (grade 1/2/3: n = 3/n =&#
apoptosis
biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets
resistance to treatment
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Obinutuzumab(Roche / Genentech)은 B-cell Lymphoma 표적 항체로, Breast Adenocarcinoma; Metastatic Breast Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: targets type I interferon signaling. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 100% (ClinicalTrials.gov NCT02611323). 차별점: novel calcineurin inhibitor with predictable pharmacokinetics, increases complete renal response rates and rapidly reduces pr.
B-cell Lymphoma
Breast Adenocarcinoma; Metastatic Breast Carcinoma
Recruiting
bispecific antibody approved for treatment of relapsed/refractory diff
AAV)
humanized type II anti-CD20 monoclonal antibody, is designed for more potent and sustained B-cell depletion w
novel calcineurin inhibitor with predictable pharmacokinetics, increases complete renal response rates and rapidly reduces pr
targets type I interferon signaling
Cytokine release syndrome occurred in all glofitamab-treated patients (grade 1/2/3: n = 3/n =&#
apoptosis
biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets
resistance to treatment
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.